RxDoctor Payments Data

Bede Cha, DO

Family Medicine · Suwanee, GANPI 1528427291

Payments from drug & device makers

$12,173in general payments, 2019–2025

Across 493 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Amgen$987
  • Johnson & Johnson$954
  • AstraZeneca$954
  • Lilly USA, LLC$645
  • plus $6K from 40 others

What the payments were for

  • Consulting fees$1,20010%
  • Travel & lodging$761%
  • Food & beverage$10,89790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,173 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$52,004
Medicare patients
194
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$106,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$87,523
MounjaroTirzepatide43$75,313
OtezlaApremilast11$62,089
FarxigaDapagliflozin Propanediol51$54,609
XareltoRivaroxaban54$47,130
GemtesaVibegron36$41,671
EliquisApixaban37$40,931
TrulicityDulaglutide14$22,948
MyrbetriqMirabegron30$20,245
LinzessLinaclotide15$18,727
JardianceEmpagliflozin12$18,270
KerendiaFinerenone11$11,132
Breo ElliptaFluticasone/Vilanterol12$8,160
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$131$106,68192 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$508$100,10598 claims
Lilly USA, LLCMounjaro, Trulicity$645$98,26157 claims
AmgenOtezla$987$62,08911 claims
AstraZenecaFarxiga$954$54,60951 claims
Johnson & JohnsonXarelto$954$47,13054 claims
Sumitomo Pharma America, Inc.Gemtesa$121$41,67136 claims
PfizerEliquis$378$40,93137 claims
AbbVieLinzess, Synthroid$1,339$21,73444 claims
Astellas Pharma US IncMyrbetriq$316$20,24530 claims
Boehringer IngelheimJardiance$508$18,27012 claims
BayerKerendia$564$11,13211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →